Paradigm

What Paradigm does

Paradigm Health is a U.S.-based healthcare technology company, founded in 2021 and headquartered in Columbus, Ohio, that operates an AI-powered clinical research platform connecting patients, healthcare provider organizations, and biopharma trial sponsors. The company has built the largest oncology research network in the United States, spanning 166 healthcare provider organizations with 2,100 care locations across 45 states — including 23 NCI-Designated Cancer Centers, 43 academic medical centers and health systems, and 123 community oncology practices — collectively reaching an estimated 70% of the U.S. cancer population and approximately 2.4 million patients following the December 2025 acquisition of Flatiron Health's Clinical Research Business. The platform serves 15 of the top 20 global biopharma companies with Phase I–III oncology trials and is the sole technology provider for the FDA's Real-Time Clinical Trials proof-of-concept studies.

The platform is composed of several integrated modules: an AI-native clinical trial matching engine built on large language models (including GPT-4) that reasons over structured EHR data and unstructured clinical notes, pathology reports, and molecular test results; an EHR-integrated eSource data capture module (eSource Casebook) that automates patient identification, enrollment, and EHR-to-database transfer with over 99% automated capture and a median 1.7-day transfer time; a Study Conduct platform for real-time safety and efficacy signal reporting to sponsors and the FDA; and SPIRE, a scalable platform for late-phase and post-approval pragmatic studies. The technology embeds directly into electronic health record environments — including Flatiron's OncoEMR via a multi-year strategic partnership — to integrate trial operations into routine clinical workflows. Compliance posture is anchored by third-party SOC 2 Type 2 and HIPAA attestations with unqualified opinions.

Paradigm generates revenue through enterprise platform agreements negotiated with biopharma sponsors and large healthcare provider organizations, structured as multi-year contracts covering trial feasibility, patient matching, site selection, EHR-integrated data collection, and regulatory reporting. Distribution combines direct enterprise sales with channel partnerships, notably Parexel for CRO-side integration, Fujitsu for the Japanese market, and Sheba Medical Center/ARC Innovation for the Israeli market. Total disclosed equity funding is approximately $281 million across a $203 million Series A (January 2023) and a $78 million Series B (December 2025), both led by ARCH Venture Partners.

Name

Paradigm

Legal name

Paradigm Health, Inc.

Website

https://paradigmhealth.ai

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Paradigm Health operates an AI-powered clinical research platform that connects biopharma sponsors, 166 healthcare provider organizations, and patients to automate clinical trial matching, EHR-integrated data capture, and real-time FDA regulatory reporting, primarily in oncology.

Ownership category

akta.pro rank

Product category

Clinical Trial Technology

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industry

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

Keywords

• Clinical trial platform
• Patient recruitment software
• EHR-integrated research
• Oncology clinical trials
• AI clinical trial matching

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform and Software Services to Sponsors and Providers: Paradigm Health provides its AI-powered clinical research platform to healthcare provider organizations (hospitals, oncology practices) and biopharma sponsors. Revenue appears to come from platform subscriptions and service fees for clinical trial execution support. The company integrates its technology into provider workflows and provides end-to-end study conduct services, including site selection, patient recruitment, feasibility, and data collection.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Paradigm Health operates an AI-powered clinical research platform that connects patients, healthcare providers, and trial sponsors to automate and streamline clinical trial execution. The platform integrates directly with electronic health records (EHRs) to perform AI-driven patient matching, site feasibility analysis, EHR-to-database data capture, and real-time safety/efficacy signal reporting for sponsors and the FDA. It serves a network of 166 healthcare provider organizations across 45 U.S. states and supports 15 of the top 20 global biopharma companies running Phase I-III oncology trials and late-phase pragmatic studies.

Product overview

Paradigm Health offers an AI-powered, end-to-end clinical research platform that connects patients, providers, and trial sponsors. The unified platform combines multiple integrated solutions including: the core Paradigm Platform for clinical trial orchestration; Study Conduct / eSource Casebook for EHR-integrated real-time data capture and FDA collaboration; SPIRE (Scalable Platform for Integrated Research & Evidence) for late-phase/post-approval evidence generation; AI-enabled Clinical Trial Matching for patient identification and enrollment; Protocol Optimization for feasibility and site selection; and a Provider Network of 166+ healthcare organizations across 45 states. The platform supports Phase I-III oncology trials for 15 of the top 20 global pharmaceutical companies and operates the largest oncology research network in the U.S.

Differentiator

Problem solved

Functional benefit

Brands

• SPIRE: Scalable Platform for Integrated Research & Evidence - an end-to-end, technology-enabled alternative to traditional CRO-led approaches for prospective, pragmatic studies, particularly for peri-approval and post-approval products with established safety profiles
• eSource Casebook
• Trial Design Service

Products and services

• Paradigm Health Platform End-to-end AI-powered clinical research platform that connects patients, healthcare providers, and trial sponsors, automating feasibility analysis, patient matching, site selection, enrollment, and real-time data capture across a nationwide network of 166 healthcare provider organizations in 45 U.S. states.
• Study Conduct Platform Real-time FDA-aligned study conduct solution that captures data directly from EHRs, algorithmically evaluates FDA-defined data points, and transmits critical safety and efficacy signals to sponsors and the FDA for ongoing regulatory review.
• eSource Casebook EHR-integrated data capture solution (formerly Clinical Pipe) that embeds research directly into the electronic health record environment, automating patient identification, enrollment, and data collection within routine clinical workflows with over 99% automated EHR-to-database transfer.
• SPIRE (Scalable Platform for Integrated Research & Evidence) End-to-end technology-enabled model for post-approval and late-stage clinical studies, combining pragmatic study design, streamlined patient recruitment, and EHR-integrated data capture across research-ready community and academic sites across 46 states.
• AI Clinical Trial Matching AI-native clinical trial matching solution using large language models (including GPT-4) to match patients to trials by reasoning over unstructured clinical notes, eligibility criteria, and structured EHR data, achieving 31-87% reduction in screening volumes and 10% higher accuracy than state-of-the-art ML models.
• Protocol Optimization & Site Selection Protocol optimization and feasibility assessment tool that enables sponsors and sites to evaluate clinical trial opportunities, verify alignment of inclusion/exclusion criteria with local patient populations, and select optimal sites based on care patterns and capabilities.

Quantifiable outcome

• 45% increase in clinical trial patient enrollment over two years at partner site
• +7 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, minor and major.

• U.S. Food & Drug Administration (FDA)coreStrategic or Co-development Partner · 28 April 2026Paradigm Health announced a landmark research collaboration with the FDA to accelerate clinical trial execution and regulatory review using its AI-powered Study Conduct platform for real-time data collection and reporting. The FDA is operationalizing proof-of-concept studies with AstraZeneca (Phase 2 TRAVERSE) and Amgen (Phase 1b STREAM-SCLC) using Paradigm's SPIRE platform, marking the first real-time clinical trial monitoring system implemented by the agency.
• Flatiron Health (a Roche affiliate)coreStrategic or Co-development Partner · 4 December 2025Paradigm Health acquired Flatiron Health's Clinical Research Business and established a multi-year strategic partnership. The transaction expanded Paradigm's network to over 25 academic medical centers and nearly 100 community oncology practices, reaching 2.4 million patients. Paradigm Health will integrate its solutions into Flatiron's OncoEMR platform (used by over 4,500 providers at 1,000+ community-based cancer care locations) and provide clinical research support to all Flatiron OncoEMR customers. The partnership creates the largest oncology research network in the United States.
• CEO Roundtable on Cancer / PACT CollectiveminorStrategic or Co-development Partner · 17 October 2025Paradigm Health partnered with the CEO Roundtable on Cancer to launch the PACT Collective, aimed at expanding clinical trial access and diversity in cancer research.
• ParexelmajorStrategic or Co-development Partner · 15 September 2025Parexel and Paradigm Health partnered to expand access and efficiency in clinical trials. Parexel incorporated Paradigm's AI-enabled clinical trial infrastructure into its service offerings, with Paradigm participating in Parexel's strategic partnerships alongside Weave Bio and Palantir under the ParexelAI initiative.
• Sheba Medical Center / ARC Innovation (Israel)majorStrategic or Co-development Partner · 12 September 2024Strategic partnership to transform clinical trials in Israel using Paradigm's AI-driven platform. The collaboration aims to scale the platform at Sheba and expand it to affiliated clinics throughout Israel, with ARC intending to expand the platform to its global ecosystem of hospitals. The Riva Koschitzky Oncology Clinical Research Unit at Sheba will serve as the lead site.
• FujitsumajorTechnology or Integration · 26 August 2024Fujitsu formed a strategic partnership with Paradigm Health to attract global clinical trials to Japan and tackle the 'drug loss' issue. Fujitsu combines Paradigm's clinical trial platform with its Healthy Living Platform and Kozuchi AI service to facilitate clinical trial planning and implementation across Japanese medical institutions. Fujitsu launched Patient-centric Clinical Trials, a new service using its proprietary LLM for automated clinical trial document creation.
• Bristol-Myers SquibbmajorStrategic or Co-development Partner · 1 January 2021A strategic partnership was announced with Bristol-Myers Squibb as one of Paradigm's early biopharma partnerships following the company's emergence from stealth.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Medidata (Dassault Systèmes): Medidata is a leading provider of clinical trial technology including EDC, CTMS, eCOA, and patient cloud platforms. It is the most direct competitor to Paradigm in clinical trial informatics, serving many of the same top 20 global biopharma sponsors with an established enterprise install base.
• Veeva Systems: Veeva offers a clinical trial suite (Vault CTMS, Vault EDC, Vault CDB) that competes with Paradigm's platform across the biopharma sponsor workflow. Veeva serves most of the same top 20 biopharma companies and represents the most prominent cloud-based incumbent in life sciences clinical operations.
• Science 37: Science 37 is a direct competitor in decentralized and technology-enabled clinical trials, with a metadata-driven platform for remote patient participation. Paradigm's CFO Jay Trepanier was previously CFO of Science 37, illustrating the close overlap in operating model and customer segment.
• Elligo Health Research: Elligo provides a research-ready site network and technology platform enabling community and rural providers to run clinical trials, with a similar GTM to Paradigm's community oncology expansion. Both companies target bringing trials closer to routine care delivery.

Broad incumbents

• Oracle Health Sciences (Clinical One): Oracle's Clinical One platform unifies EDC, RTSM, clinical trial supply, and analytics for biopharma sponsors. As a broad incumbent, Oracle competes with Paradigm in eSource and trial data collection, with deep enterprise penetration from its prior InForm and Siebel CTMS franchises.
• IQVIA: IQVIA is the largest global CRO and life sciences technology provider, with significant clinical trial technology assets (e.g., E360, OCE, Patient Engagement) and the scale to bundle competing offerings to the same top 20 biopharma clients that Paradigm serves.
• ICON plc: ICON is a global CRO formed from the PRA Health Sciences merger, where Paradigm's CEO previously served. ICON competes across clinical trial services and increasingly technology-enabled trial execution, overlapping with Paradigm's SPIRE-style late-phase model.

Emerging players

• Tempus AI: Tempus AI operates a molecular data and AI platform increasingly used for clinical trial matching and patient identification in oncology. It overlaps with Paradigm's AI-native matching and biomarker-driven enrollment, and competes for the same biopharma R&D and site ecosystem.
• Advarra: Advarra provides technology and services for clinical research sites, sponsors, and IRBs, including CTMS, eRegulatory, and feasibility tools. It overlaps with Paradigm's site-facing platform modules and serves a similar provider customer base.

Others

• Flatiron Health: Flatiron Health (a Roche affiliate) sold its Clinical Research Business to Paradigm in December 2025 and entered a multi-year strategic partnership. Flatiron remains a peer in oncology EHR data and research operations, but is now an integrated partner rather than direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/paradigminc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paradigm